Termination of nelotanserin, a small molecule licensed from Arena, in Lewy body dementias comes after a dramatic shift toward gene therapy.
Axovant Sciences Ltd. declared it was closing a chapter on its small molecule efforts after the failure of the 5-H2A receptor agonist nelotanserin in Lewy body dementias (LBD), as it continues to focus on its new gene therapy portfolio.
CNS-focused Axovant is one of 14 "Vants" or subsidiaries in various therapeutic areas of parent company Roivant Sciences GMBH....
Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.
